ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi...
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Business Wire
Executive Accountability: Michael Alferi Named in Securities Action NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors that Michael Alferi, Head of Finance, principal financial officer, and principal accounting officer of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), is named as an individual defendant in a securities class action covering purchases between November 3, 2023 and March 16, 2026. Find out if you can recover losses tied to this executive's alleged misconduct. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.Aldeyra shares lost $2.99 per share, a 70.7% decline, after the FDA issued a Complete Response Letter rejecting reproxalap for dry eye disease. The lead plaintiff deadline is May 29, 2026.Michael Alferi's Role During the Class PeriodAlferi assumed the role of Head of Finance, principal financial officer, and principal accounting officer on August 31, 2024, the action contends. From that date forward, Alferi co-sign
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDXGlobeNewswire
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026PR Newswire
- ALDX Shareholder Alert: Aldeyra Therapeutics, Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law FirmPR Newswire
- ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law FirmPR Newswire
ALDX
Earnings
- 11/5/25 - Beat
ALDX
Sec Filings
- 4/20/26 - Form 8-K
- 4/1/26 - Form 8-K
- 3/31/26 - Form 4
- ALDX's page on the SEC website